Please login to the form below

Not currently logged in
Email:
Password:

Takeda UK & Ireland appoints market access director

Peter Wheatley Price brings experience from GSK, Janssen and Boehringer Ingelheim

Takeda UK & Ireland Peter Wheatley PriceTakeda UK & Ireland has appointed Peter Wheatley Price as market access director, succeeding Ross Selby who moves to head the firm's new US-based global pricing, market access and health economics oncology division.

Wheatley Price joins Takeda from GlaxoSmithKline, where he served as global market access and pricing director from 2014 to January this year, during which time he oversaw the launch of the company's first respiratory biologic for severe asthma.

Prior to this, Wheatley Price was associate director of health economics market access and reimbursement for oncology across Europe, the Middle East and Africa at Janssen, having joined as interim head of outcomes research in 2010.

He also brings experience form Boehringer Ingelheim, where he was director of its UK Change Project, head of UK market access for prescription medicines, and held a series of marketing management positions.

Adam Zaeske, managing director of Takeda UK, said: “Owing to our ambitions to continue to deliver improved outcomes both for patients and our customers, I am delighted that we have been able to attract such a strong talent as Peter to take on such an important role in our organisation.

“It is clear to me that he shares our vision for Takeda and has both the experience and passion to help us to grow the business.”

27th January 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

ACCOMPLISH MEANINGFUL HCP ENGAGEMENT ONLINE
The art of delivering valuable customer journeys aligned to your key messages in 2020...
DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...

Infographics